GLPwatch
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
J Fam Pract · 2017
Last updated 2026-05-28Since 2005, five GLP-1 receptor agonist medications—liraglutide, albiglutide, dulaglutide, lixisenatide, and a once-weekly exenatide—have been approved for treating type 2 diabetes. Additionally, semaglutide and a new exenatide delivery method using an osmotic mini-pump are currently under FDA review.
AI summary of the abstract below.
| Journal | J Fam Pract, 2017 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Since 2005, four new GLP-1RAs (liraglutide, albiglutide, dulaglutide, and lixisenatide) and a once-weekly formulation of exenatide were approved for the treatment of persons with T2DM. Another GLP-1RA, semaglutide, is under review by the FDA, as is exenatide administered via an osmotic mini-pump.
Verbatim abstract via PubMed 28991932 ↗